title: Congenital hypothyroidism: etiologies, diagnosis, and management.
abstract: Congenital hypothyroidism is a common preventable cause of mental retardation. The overall incidence is approximately 1:4000; females are affected about twice as often as males. Approximately 85% of cases are sporadic, while 15% are hereditary. The most common sporadic etiology is thyroid dysgenesis, with ectopic glands more common than aplasia or hypoplasia. While the pathogenesis of dysgenesis is largely unknown, some cases are now discovered to be the result of mutations in the transcription factors PAX-8 and TTF-2. Loss of function mutations in the thyrotropin (TSH) receptor have been demonstrated to cause some familial forms of athyreosis. The most common hereditary etiology is the inborn errors of thyroxine (T4) synthesis. Recent mutations have been described in the genes coding for the sodium/iodide symporter, thyroid peroxidase (TPO), and thyroglobulin. Transplacental passage of a maternal thyrotropin receptor blocking antibody (TRB-Ab) causes a transient form of familial congenital hypothyroidism. The vast majority of infants are now diagnosed after detection through newborn screening programs using a primary T4-backup TSH or primary TSH test. Screening test results must be confirmed by serum thyroid function tests. Thyroid scintigraphy, using 99mTc or 123I, is the most accurate diagnostic test to detect thyroid dysgenesis or one of the inborn errors of T4 synthesis. Thyroid sonography is nearly as accurate, but it may miss some cases of ectopic glands. If maternal antibody-mediated hypothyroidism is suspected, measurement of maternal and/or neonatal TRB-Ab will confirm the diagnosis. The goals of treatment are to raise the serum T4 as rapidly as possible into the normal range, adjust the levothyroxine dose with growth to keep the serum T4 (or free T4) in the upper half of the normal range and the TSH normal, and maintain normal growth and development while avoiding overtreatment. An initial starting dose of 10-15 microg/kg per day is recommended; this dose will decrease on a weight basis over time. Serum T4 (or free T4) and TSH should be monitored every 1-2 months in the first year of life and every 2-3 months in the second and third years.
authors.affiliation: Department of Pediatrics, Oregon Health Sciences University, Portland 97201, USA. lafrancs@ohsu.edu
authors.forename: S
authors.initials: S
authors.lastname: LaFranchi
mesh_terms: D003409:Congenital Hypothyroidism; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D051858:Forkhead Transcription Factors; D006801:Humans; D007037:Hypothyroidism / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D015994:Incidence; D007231:Infant, Newborn; D008607:Intellectual Disability / Q000209:etiology*; D008297:Male; D008661:Metabolism, Inborn Errors / Q000235:genetics / Q000503:physiopathology; D009154:Mutation; D009687:Nuclear Proteins; D000072636:PAX8 Transcription Factor; D051761:Paired Box Transcription Factors; D011989:Receptors, Thyrotropin / Q000235:genetics; D012097:Repressor Proteins / Q000235:genetics; D013961:Thyroid Gland / Q000002:abnormalities; D013974:Thyroxine / Q000096:biosynthesis; D015534:Trans-Activators / Q000235:genetics
chemical_list: D004268:DNA-Binding Proteins; C106894:FOXE1 protein, human; D051858:Forkhead Transcription Factors; D009687:Nuclear Proteins; D000072636:PAX8 Transcription Factor; C083325:PAX8 protein, human; D051761:Paired Box Transcription Factors; D011989:Receptors, Thyrotropin; D012097:Repressor Proteins; D015534:Trans-Activators; D013974:Thyroxine